Medivir's partner Tibotec announced that final SVR24 results from phase IIb PILLAR study of TMC435 will be presented at the AASLD meeting today
HUDDINGE, Sweden--(BUSINESS WIRE)--Nov 7, 2011 - Regulatory News:
Medivir AB (STO:MVIR), the research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced that safety and efficacy results from the phase IIb PILLAR study of once-daily TMC435 in treatment-naïve patients infected with hepatitis C will be presented as an oral late-breaker at the AASLD meeting in San Francisco, USA today.
Tibotec released the following statement on 5th November 2011:
Tibotec to present final safety and efficacy results from phase 2b PILLAR study of Once-daily TMC435 in late-breaker at AASLD
-- Data show high rates of virologic response and shortened treatment duration; safety and tolerability comparable to placebo --
[San Francisco, CA. Saturday 5th November 2011] – Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.
Results from the final PILLAR analysis showed that TMC435 administered in combination with peginterferon Î±-2a and ribavirin (PR) resulted in significantly higher sustained virologic response (SVR) rates compared to placebo plus PR. In the two TMC435 treatment groups who received TMC435 75mg, between 75 and 82 percent of patients achieved SVR24, and in the two TMC435 treatment groups who received TMC435 150mg, between 81 and 86 percent of patients achieved SVR24. This is compared to 65 percent of patients in the placebo arm who achieved SVR24. In addition, 79 to 86 percent of patients in the TMC435 treatment arms had a shortened treatment duration of 24 weeks, compared to a 48 weeks treatment duration for patients who received placebo plus P/R. In TMC435 arms, 68 to 76 percent of patients achieved rapid virologic response [RVR; HCV RNA<25 (undectectable)], of whom 88 to 95 percent achieved SVR24. There were no significant differences for adverse events between TMC435 treatment groups and placebo. TMC435 150mg administered once daily (q.d.) is being investigated in phase 3 trials in treatment-naive patients and in patients who experienced a viral relapse after being treated with interferon-based therapy. TMC435 is being developed by Tibotec Pharmaceuticals. Medivir AB has commercialization rights for TMC435 for the Nordic countries, Janssen has commercialization rights for TMC435 in the rest of the world.
The PILLAR study [Protease Inhibitor TMC435 trial assessing the optimaL dose and duration as once daiLy Anti-viral Regimen] (TMC435-C205; NCT00882908) was a five-arm, global phase 2b randomized, double-blind, placebo controlled study in 386 treatment-naive patients. TMC435 was administered in doses of 75mg or 150mg q.d. for either 12 weeks or 24 weeks in combination with 24 or 48 weeks of peg-interferon and ribavirin (PR). Patients in the placebo arm receive 24 weeks of placebo plus peg-interferon and ribavirin followed by 24 additional weeks of peg-interferon and ribavirin treatment. The primary endpoint of the study was sustained virologic response at Week-72 (SVR week 72). The PILLAR study was conducted in 13 countries in Europe, North America, and Australasia. Patients receiving TMC435 were allowed to stop all treatment at week 24 if they met both response-guided criteria: a) detectable or undetectable HCV RNA levels (< 25 IU/mL) at week 4 and b) undetectable HCV RNA at weeks 12, 16 and 20. Patients who did not meet the above response-guided criteria continued with peg-interferon and ribavirin until Week-48.
“HCV is a devastating problem worldwide and remains a leading cause of cirrhosis, liver cancer, and liver transplantation,” said Dr. Michael W. Fried M.D., lead clinical investigator and Professor of Medicine, Director, UNC Liver Center, University of North Carolina at Chapel Hill. “We are extremely encouraged by the success of once-daily TMC435 in achieving significantly higher SVR compared to control group and look forward to furthering its development in recently launched phase 3 trials.”
The goal of HCV treatment is to achieve SVR24, which means the virus is undetectable in patients' blood six months after they have finished treatment. Patients who achieve SVR are considered cured.
The most common adverse events (AEs) in the PILLAR study were headache and fatigue, 46 percent and 42 percent in the TMC435 groups and 51 percent and 47 percent in the placebo group respectively. There were no clinically significant differences in frequency of rash, anemia or gastrointestinal events between the TMC435 groups and placebo. Most AEs were mild to moderate in severity. AEs leading to treatment discontinuation of TMC435/placebo were reported in 7.1 percent of patients in TMC435 arms and 7.8 percent in placebo arm.
“Tibotec is pleased to present the final results of the phase 2b PILLAR study at AASLD. The continued development of TMC435, which is currently being investigated in registrational phase 3 studies, reinforces our strong commitment to the development of new therapies that may reduce treatment duration and improve the lives of those impacted by HCV,” said Maria Beumont M.D., Global Medical Leader TMC435 at Tibotec.
In conjunction with the final sustained virologic response (SVR) results from PILLAR, Tibotec is presenting virology analysis data from PILLAR and two sets of early study results on the effects of co-administering TMC435 and methadone and its interaction with the antidepressant escitalopram, to be featured in 3 posters at AASLD:
- “TMC435 in combination with peginterferon alpha-2a/ribavirin in treatment-naïve patients infected with HCV genotype 1: virology analysis of the PILLAR study.” O. Lenz.
- “The pharmacokinetic interaction between the investigational NS3-4A HCV protease inhibitor TMC435 and methadone.” M. Beumont-Mauviel.
- “The pharmacokinetic interaction between the investigational HCV NS3/4A protease inhibitor TMC435 and escitalopram.” M. Beumont-Mauviel.
Tibotec is currently conducting two global, phase 3 registrational trials to examine TMC435 in treatment-naïve adults with chronic genotype 1 hepatitis C virus (HCV). A third global phase 3 trial is being conducted in genotype 1 HCV patients who have experienced a viral relapse after prior interferon-based treatment. All three studies are fully randomized.
TMC435 is a highly potent and selective once-daily (q.d.) investigational drug that is being jointly developed by Tibotec Pharmaceuticals and Medivir to treat chronic hepatitis C virus infections.
TMC435 has received “Fast Track” designation by the U.S. Food and Drug Administration (“FDA”) for the treatment of chronic hepatitis C (CHC) genotype-1 infection. This is based on TMC435's potential to address unmet medical needs in the treatment of chronic HCV infection. TMC435 is currently being developed in three global phase III studies, QUEST-1 and QUEST-2 in treatment-naïve patients and PROMISE in patients who have relapsed after prior interferon-based treatment. In parallel with these trials, phase III studies for TMC435 in Japan, in both treatment naive and treatment experienced hepatitis C genotype-1 infected patients, are ongoing.
About Hepatitis C
Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost three million people in the United States are chronically infected with HCV.
Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is TMC435, a novel protease inhibitor that is in phase III clinical development for hepatitis C and is partnered with Tibotec Pharmaceuticals.
In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialization of TMC435 in the Nordic markets, once approved.
Medivir's first product, the unique cold sore product Xerese®/Xerclear®, was launched on the US market in February 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe is partnered with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.
For more information about Medivir, please visit the Company's website: www.medivir.com.
This information was brought to you by Cision http://www.cisionwire.com
Rein Piir, EVP Corporate Affairs & IR
Mobile: +46 708 537 292
Peter Laing, Amber Bielecka, Claire Dickinson
+44(0)20 7920 2330
Roland Tomforde +1 212 232 2356
Posted: November 2011